Ultragenyx Says Week 96 Phase 3 Data On GENGLYCOS In Glycogen Storage Disease Type Ia Show 61% Mean Reduction In Daily Cornstarch Intake, With 33% Of Treatment Group And 42% Of Crossover Group Eliminating Nighttime Dosing

Loading news article.

Ultragenyx Says Week 96 Phase 3 Data On GENGLYCOS In Glycogen Storage Disease Type Ia Show 61% Mean Reduction In Daily Cornstarch Intake, With 33% Of Treatment Group And 42% Of Crossover Group Eliminating Nighttime Dosing | WAPE

Ultragenyx Says Week 96 Phase 3 Data On GENGLYCOS In Glycogen Storage Disease Type Ia Show 61% Mean Reduction In Daily Cornstarch Intake, With 33% Of Treatment Group And 42% Of Crossover Group Eliminating Nighttime Dosing

Article summary

Related companies

Comments —